

## AHA SCIENTIFIC STATEMENT

# Adverse Pregnancy Outcomes and Cardiovascular Disease Risk: Unique Opportunities for Cardiovascular Disease Prevention in Women

## A Scientific Statement From the American Heart Association

**ABSTRACT:** This statement summarizes evidence that adverse pregnancy outcomes (APOs) such as hypertensive disorders of pregnancy, preterm delivery, gestational diabetes, small-for-gestational-age delivery, placental abruption, and pregnancy loss increase a woman's risk of developing cardiovascular disease (CVD) risk factors and of developing subsequent CVD (including fatal and nonfatal coronary heart disease, stroke, peripheral vascular disease, and heart failure). This statement highlights the importance of recognizing APOs when CVD risk is evaluated in women, although their value in reclassifying risk may not be established. A history of APOs is a prompt for more vigorous primordial prevention of CVD risk factors and primary prevention of CVD. Adopting a heart-healthy diet and increasing physical activity among women with APOs, starting in the postpartum setting and continuing across the life span, are important lifestyle interventions to decrease CVD risk. Lactation and breastfeeding may lower a woman's later cardiometabolic risk. Black and Asian women experience a higher proportion APOs, with more severe clinical presentation and worse outcomes, than White women. More studies on APOs and CVD in non-White women are needed to better understand and address these health disparities. Future studies of aspirin, statins, and metformin may better inform our recommendations for pharmacotherapy in primary CVD prevention among women who have had an APO. Several opportunities exist for health care systems to improve transitions of care for women with APOs and to implement strategies to reduce their long-term CVD risk. One proposed strategy includes incorporation of the concept of a fourth trimester into clinical recommendations and health care policy.

Nisha I. Parikh, MD, MPH,  
Chair

Juan M. Gonzalez, MD  
Cheryl A.M. Anderson,  
PhD

Suzanne E. Judd, PhD  
Kathryn M. Rexrode, MD  
Mark A. Hlatky, MD  
Erica P. Gunderson, PhD  
Jennifer J. Stuart, ScD  
Dhananjay Vaidya, PhD,  
Vice Chair

On behalf of the American  
Heart Association  
Council on Epidemiology  
and Prevention; Council  
on Arteriosclerosis,  
Thrombosis and Vascular  
Biology; Council on  
Cardiovascular and  
Stroke Nursing; and the  
Stroke Council

**Key Words:** AHA Scientific Statements  
■ cardiovascular diseases ■ pregnancy  
■ pregnancy complications ■ primary  
prevention ■ risk factors

© 2021 American Heart Association, Inc.

<https://www.ahajournals.org/journal/circ>

Pregnancy leads to many vascular, metabolic, and physiological adaptations in the mother, including increased insulin resistance, adipose deposition, hypercoagulability, cardiac remodeling, and decreased vascular resistance. These changes support fetal growth and development and prepare the mother for the increased energy and nutritional demands of lactation to support the newborn's postnatal growth.<sup>1</sup> The physiological stress of pregnancy may unmask adverse maternal and fetal pregnancy outcomes (APOs) such as gestational diabetes (GD), hypertensive disorders of pregnancy, intrauterine growth restriction, small-for-gestational age (SGA) delivery, placental abruption, and preterm delivery in women with prepregnancy elevated cardiometabolic risk factors or genetic or environmental predisposition to these abnormalities<sup>2–5</sup> (Table 1).

For instance, women with prepregnancy insulin resistance, a family history of diabetes, or elevated blood pressure are more likely to develop GD during their pregnancy compared with women without these predisposing factors.<sup>21</sup> Similarly, women with obesity and elevated prepregnancy blood pressures are more susceptible to

developing preeclampsia or gestational hypertension.<sup>22</sup> Fetal size is determined by several factors, including maternal and paternal age, genetics, nutrition, interpregnancy interval, and parity. A baby who is determined to be SGA (according to their birth weight for gestational age) may have been affected by placental insufficiency (resulting from insufficient implantation of the placenta into the uterus) or vascular insufficiency (caused by abnormal maternal uterine artery flow resulting in an inability to supply adequate oxygen and nutrients to the placental or fetal unit). Thus, having a small baby, that is, an SGA baby, a baby with low birth weight, or a baby with fetal (intrauterine) growth restriction, may uncover preexisting vascular dysfunction in the mother that later predisposes her to cardiovascular disease (CVD; including coronary heart disease, stroke, and heart failure). Experiencing an APO may also accentuate cardiovascular and metabolic risk factor trajectories for women, which also contributes to the higher risk of subsequent CVD.<sup>23</sup> Because response to the stress of pregnancy is a harbinger of women's later CVD risk, the 2011 update of the American Heart Association effectiveness-based guidelines for the prevention of CVD

**Table 1. Obstetric Definitions and Prevalence of APOs**

Term/condition	Definition	Women with condition, %
APO	One of several maternal or fetal complications, including preeclampsia, gestational hypertension, GD, preterm delivery, fetal growth restriction, having a neonate with a low birth weight or a low birth weight indexed to a referent sample based on gestational age (SGA), and placental abruption.	10–15 <sup>6,7*</sup>
Preeclampsia	Pregnancy disorder associated with new-onset hypertension, which occurs most often after 20 wk of gestation and frequently near term. It is often but not always accompanied by new-onset proteinuria.	2–8 <sup>†</sup>
Gestational hypertension	Defined as a systolic blood pressure of $\geq 140$ mm Hg, a diastolic blood pressure of $\geq 90$ mm Hg, or both on 2 occasions at least 4 h apart after 20 wk of gestation in a woman with a previously normal blood pressure.	2–3 <sup>†</sup>
Hypertensive disorder of pregnancy <sup>10</sup>	Preeclampsia, chronic hypertension, chronic hypertension with superimposed preeclampsia, eclampsia, or gestational hypertension.	6–8 <sup>11†</sup>
GD	Any degree of glucose intolerance with onset or first recognition during pregnancy.	2–10 <sup>12</sup>
Gestational age	Time elapsed since the first day of the last menstrual period (also known as menstrual age).	...
Placental abruption	Premature separation of a normally implanted placenta from the uterus before delivery of the fetus.	1 <sup>13†</sup>
Preterm delivery	After 20 wk gestation and before the completion of 37 wk of gestation regardless of birth-weight.	10 <sup>14†</sup>
Low birth weight	Neonate with birthweight $< 2500$ g (or $< 5$ lb 8 oz).	8 <sup>14†</sup>
SGA	Neonate whose weight is below the 10th percentile for the gestational age based on a reference standard (often national reference standards for weight for gestational age. Other defined cut points include weight below the third percentile). Some published cut points are sex and race specific. Reference standards generally have excluded nonsingleton deliveries and congenital malformations. <sup>15</sup>	10 <sup>16</sup>
Large for gestational age	Neonate whose weight is above the 90th percentile for the gestational age.	8–13 <sup>17</sup>
Fetal growth restriction (intrauterine growth restriction)	Condition in which a fetus is unable to achieve its genetically determined potential size. <sup>18,19</sup> Fetal growth restriction describes fetuses with an estimated fetal weight that is less than the 10th percentile for gestational age. To assess for fetal growth restriction, 4 biometric measures are commonly used: (1) biparietal diameter, (2) head circumference, (3) abdominal circumference, and (4) femur length. The biometric measurements can be combined to generate an estimated fetal weight. <sup>20</sup>	5–15 <sup>8,19†</sup>

APO indicates adverse pregnancy outcome; GD, gestational diabetes; and SGA, small for gestational age.

\*Across all of a woman's pregnancies.

†Per pregnancy or delivery.

**Table 2.** APOs and Associations With Mortality and CVD Outcomes

Pregnancy outcome/ reproductive risk factors	Outcome association	Strength of Evidence*
Hypertensive disorders of pregnancy (preeclampsia, gestational hypertension)	↑ Atherosclerotic CVD (including coronary heart disease, peripheral vascular disease, and ischemic stroke)	A
	↑ Hemorrhagic stroke	B
	↑ Heart failure	B
GD	↑ Atherosclerotic CVD	A
Preterm delivery	↑ Atherosclerotic CVD	A
SGA	↑ Atherosclerotic CVD	A
Large for gestational age	↑ Atherosclerotic CVD	B
Placental abruption	↑ Atherosclerotic CVD	A
Miscarriages/stillbirths	↑ Atherosclerotic CVD	A

APO indicates adverse pregnancy outcome; CVD, cardiovascular disease; GD, gestational diabetes; and SGA, small for gestational age.

See Supplemental Table 1 for specific studies and references.

\*Strength of Evidence A indicates multiple consistent cohort studies, meta-analyses of such studies, or both. Strength of Evidence B indicates fewer available studies or inconsistencies in the evidence.

in women recommends that a history of APOs (GD, preeclampsia, preterm birth, or birth of an SGA infant) should be considered part of CVD risk assessment in women.<sup>24</sup> Furthermore, the updated 2018 cholesterol treatment guidelines briefly list these APOs as CVD risk enhancers that would be critical to consider when deciding on use of a statin for CVD prevention.<sup>25</sup> This current American Heart Association statement reviews the epidemiological evidence relating individual APOs and CVD risk and discusses potential lifestyle modifications to ameliorate this risk among women with a history of APOs. We also consider health systems approaches that could dually enhance women's long-term cardiovascular health and improve the health of her future pregnancies after an APO.

## PREGNANCY COMPLICATIONS AND THE RISK OF CVD EVENTS

There is a substantial and consistent body of evidence showing that APOs, including hypertensive disorders of pregnancy, preterm delivery, GD, delivering an SGA baby, placental abruption, and pregnancy loss, are associated with clinical CVD events in later life (Table 2 and Supplemental Table 1). The body of evidence was considered strong (Strength of Evidence A) for meta-analyses that tested for (and excluded) publication bias and for primary studies based on objective contemporaneous record of pregnancy complications.

### Hypertensive Disorders of Pregnancy

A history of gestational hypertension has consistently been associated with an increased risk of CVD (odds

ratio [OR], 1.67 [95% CI, 1.28–2.19]; meta-analysis of 9 studies)<sup>26</sup> and with increased odds of stroke (OR, 1.83 [95% CI, 1.79–4.22]; a meta-analysis of 4 studies).<sup>26</sup> The associations with CVD were progressively stronger for moderate preeclampsia (OR, 2.24 [95% CI, 1.74–1.93]) and severe preeclampsia (OR, 2.74 [95% CI, 2.48–3.04]).<sup>26</sup> Other meta-analyses and more recent primary studies show similar associations of these hypertensive disorders of pregnancy with CVD.<sup>27–37</sup>

### Gestational Diabetes

A history of GD was associated with CVD (OR, 1.68 [95% CI, 1.11–2.52]) in a meta-analysis of 8 studies,<sup>26</sup> which was confirmed by another systematic review with similar consolidated results.<sup>38</sup>

### Preterm Delivery

Preterm delivery was associated with CVD mortality (OR, 1.93 [95% CI, 1.83–2.03]) in a recent meta-analysis of 4 studies.<sup>26</sup> Although 1 recent study showed no association of preterm delivery with future CVD,<sup>30</sup> a large body of other studies and meta-analyses demonstrate strong associations of preterm delivery (alone and in conjunction with hypertensive disorders of pregnancy) with coronary heart disease, stroke, and CVD.<sup>29,33,39,40</sup>

### Birth Weight

Delivering an SGA baby was nonsignificantly associated with CVD (OR, 1.29 [95% CI, 0.91–1.83]) in a recent meta-analysis of 4 studies,<sup>26</sup> largely consistent with other individual studies and meta-analyses (some of which had statistically significant associations that were similar in magnitude).<sup>29,30,33,36,41,42</sup> One study suggested that a large-for-gestational-age delivery might also be associated with increased risk of CVD (hazard ratio [HR], 3.0 [95% CI, 2.0–4.6]).<sup>43</sup>

### Pregnancy Loss and Placental Abruption

A history of placental abruption was associated with increased risk of CVD (HR, 1.82 [95% CI, 1.42–2.33]) in a recent meta-analysis of 4 studies.<sup>26</sup> Stillbirth was also associated with increased risk of CVD (HR, 2.23 [95% CI, 1.92–2.62]).<sup>26</sup> Other individual studies have also shown an association between pregnancy loss (miscarriages or stillbirths or combined) and future cardiovascular events.<sup>29,44–46</sup>

## PREGNANCY COMPLICATIONS IN ASSOCIATION WITH LATER CVD RISK FACTORS

Most APOs are associated with future development of ≥1 CVD risk factors, including hypertension, diabetes, and dyslipidemia, which may, in part, mediate the

**Table 3.** Summary of Studies of APOs and CVD Risk Factors: Results From Meta-Analyses and Individual Studies

	Elevated blood pressure/hypertension	Diabetes (or hyperglycemia)	Dyslipidemia
Hypertensive disorders of pregnancy	M+*	M++†	M+§
GD mellitus	+ <sup>47</sup> — <sup>48</sup>	M+	+ <sup>49</sup> — <sup>50,51</sup>
Preterm delivery	+ <sup>39,48,52–54</sup> — <sup>51,55</sup>	+ <sup>39,55</sup> — <sup>51</sup>	+ <sup>39,55</sup> — <sup>51,53,56</sup>
SGA	+ <sup>48,53</sup> — <sup>55</sup>	+ <sup>55</sup>	— <sup>53</sup>
Pregnancy loss	+ <sup>44,57,58</sup>	+ <sup>58</sup>	+ <sup>58</sup> — <sup>44</sup>

APO indicates adverse pregnancy outcomes; CVD, cardiovascular disease; GD, gestational diabetes; M, meta-analysis; SGA, small for gestational age; +, positive association; and —, negative association.

Meta-analyses results:

\*Preeclampsia and hypertension,<sup>59</sup> 32 studies (relative risk, 3.13 [95% CI, 2.51–3.89]).

†Preeclampsia and type 2 diabetes,<sup>60</sup> 10 studies (relative risk, 2.25 [95% CI, 1.73–2.90]).

‡Gestational hypertension and type 2 diabetes,<sup>60</sup> 7 studies (relative risk, 1.56 [95% CI, 1.21–2.01]).

§Hypertensive disorders of pregnancy and dyslipidemia<sup>61</sup>: 0.13 mmol/L (95% CI, 0.05–0.21) for triglycerides (10 studies), 0.22 mmol/L (95% CI, 0.11–0.33) for total cholesterol (11 studies), –0.11 mmol/L (95% CI, –0.18 to –0.04) for high-density lipoprotein cholesterol (10 studies), and 0.21 mmol/L (95% CI, 0.10–0.32) for low-density lipoprotein cholesterol (9 studies).

||GD and type 2 diabetes,<sup>62</sup> 20 studies (relative risk, 9.51 [95% CI, 7.14–12.67];  $P<0.001$ ).

increased risk of late CVD that has consistently been documented in meta-analyses (Table 3). Placental abruption has not been well studied in terms of its association with later CVD risk factors.

## Hypertensive Disorders of Pregnancy and CVD Risk Factors

The evidence is strong that women who experienced preeclampsia have a much higher risk of subsequently developing chronic hypertension. A meta-analysis of 43 studies found a pooled risk ratio for hypertension of 3.13 (95% CI, 2.51–3.89) after preeclampsia.<sup>59</sup> Prior pooled data suggest that 20% of women with preeclampsia develop hypertension within 15 years.<sup>63</sup> Thus, screening programs for hypertension could begin in a woman's fourth decade.<sup>63</sup> Women with hypertensive disorders of pregnancy also have a greater risk of developing subsequent diabetes<sup>60</sup> and lipid abnormalities.<sup>61</sup>

## GD and CVD Risk Factors

GD is well established as a risk factor for the development of later type 2 diabetes, with a nearly 10-fold elevation in type 2 diabetes across 20 studies<sup>62</sup> (risk ratio, 9.51 [95% CI, 7.14–12.67]). The risk of developing type 2 diabetes

after GD was higher in women with a higher body mass index, a family history of diabetes, multiparity, advanced maternal age, and more severe GD and in those with concomitant hypertensive disorders of pregnancy or preterm delivery.<sup>64</sup> The associations between GD and subsequent development of hypertension,<sup>47,48</sup> and dyslipidemia<sup>49–51</sup> have been inconsistent across studies.

## Preterm Delivery and CVD Risk Factors.

Evidence for an association between preterm delivery and CVD risk factors is less strong than for hypertensive disorders of pregnancy or GD (with CVD risk factors). Five prior studies demonstrated that preterm delivery is associated with elevated blood pressure and a greater risk of hypertension later in life.<sup>39,48,52–54</sup> The earlier in pregnancy that preterm delivery occurs, the more strongly it is associated with later development of high blood pressure.<sup>48</sup> The association between preterm delivery and later high blood pressure may be the result of its close association with hypertensive disorders of pregnancy.<sup>51,55</sup> Preterm delivery was a modest risk factor for later type 2 diabetes in some<sup>39,55</sup> but not all<sup>51</sup> prior studies. Evidence for the association of preterm birth with dyslipidemia is inconsistent, with 2 positive<sup>39,55</sup> and 3 negative studies.<sup>51,53,56</sup>

## SGA Delivery and CVD Risk Factors

Delivery of an SGA baby has been associated with later elevations in maternal systolic<sup>48,51</sup> and diastolic blood pressures<sup>53</sup> and with hypertension,<sup>48,51</sup> although a fourth smaller study found no such associations.<sup>55</sup> SGA birth is also associated with later development of diabetes<sup>53</sup> and elevated fasting glucose<sup>55</sup> but not with lipid abnormalities.<sup>53</sup>

## Pregnancy Loss and CVD Risk Factors

All forms of pregnancy loss are associated with risk of elevated blood pressure<sup>44</sup> or hypertension,<sup>44,57,58</sup> with a particularly higher risk for hypertension after either late-term or recurrent pregnancy loss.<sup>26,43,44</sup> Women with spontaneous pregnancy loss or stillbirth also have higher rates of type 2 diabetes in later life.<sup>44,58</sup> Evidence for an association between pregnancy loss and dyslipidemia has been mixed,<sup>44</sup> but the Nurses' Health Study has found that women with spontaneous abortion had modestly elevated risks of hypercholesterolemia.<sup>58</sup>

## STUDIES ASSESSING THE UTILITY OF APOS IN CVD RISK STRATIFICATION

Relatively few published studies have rigorously evaluated the utility of adding information about APOs to conventional CVD risk stratification.<sup>30,34,36,45</sup> These



studies suggest that although APOs may provide an early window to the development of CVD, they may not materially add to CVD prediction or to net reclassification of CVD after accounting for established risk factors. The incremental information provided by APOs may have been partly captured by any subsequent increases in hypertension, diabetes, and dyslipidemia. Prior studies have evaluated the additional information provided by the following APOs: pregnancy loss,<sup>45</sup> hypertensive disorders of pregnancy,<sup>34</sup> preterm delivery and preeclampsia,<sup>36</sup> and preeclampsia, gestational hypertension, preterm delivery, or SGA delivery.<sup>30</sup> The incremental predictive capacity of APOs may be limited by their lower prevalence compared with traditional CVD risk factors and the more contemporary data provided by current risk factor levels. Moreover, CVD risk stratification studies considering APOs have been conducted in middle-aged and older women, and by these ages, women are more likely to have developed conventional CVD risk factors, thereby limiting the potential contribution of APOs to identifying women at higher long-term risk for CVD.

## LIFESTYLE MODIFICATION FOR CVD RISK FACTOR REDUCTION AMONG WOMEN WITH APOS

### Dietary Patterns to Optimize Cardiovascular Health in Women of Reproductive Age and Pregnant Women

Healthy dietary patterns can optimize the cardiovascular health of all women, which may be especially important before pregnancy.<sup>65,66</sup> Epidemiological cohort studies suggest that healthy dietary patterns up to 3 years before pregnancy (ie, characterized by high intake of fruits, vegetables, legumes, nuts, and fish and low intake of red and processed meats) are associated with lower risks of hypertensive disorders of pregnancy, GD, and preterm delivery.<sup>67</sup> Maternal nutrition in the 12 months before conception may affect fetal growth, development, gestational age, and infant birth weight.<sup>68</sup> Among women with uncomplicated pregnancies, the DASH (Dietary Approaches to Stop Hypertension) diet was associated with lower blood pressure than other dietary patterns.<sup>69</sup> A diet high in protein and fruits was associated with a lower risk of preterm delivery, whereas a diet high in fat and sugar was associated with an increased risk for preterm delivery in 1 study.<sup>68</sup> Among women with GD, the DASH diet was associated with better pregnancy outcomes, including a lower use of insulin.<sup>70</sup> Following the DASH diet during pregnancy was associated with a decreased risk of preterm delivery in a separate study.<sup>71</sup> These associations could be confounded by other favorable lifestyle

and medical factors, yet recommending consumption of a healthy dietary pattern is widely accepted. The American College of Obstetricians and Gynecologists has not specifically endorsed or counseled against a DASH diet during pregnancy and postpartum, and it is likely important for more scientific studies to be conducted to confirm efficacy.

### Special Considerations to Optimize Dietary Intake in Women of Reproductive Age and in Pregnant Women With GD or Preeclampsia

It is recommended that women of reproductive age consume supplemental folate and iron in addition to a healthy dietary pattern.<sup>72,73</sup> Adherence to dietary and physical activity recommendations may reduce the risk of developing GD.<sup>74</sup> The higher risk of developing type 2 diabetes among women who had GD suggests that adoption of a healthy diet may be particularly valuable in preventing late diabetes.<sup>75,76</sup> Although a strong body of evidence documents the effect of a healthy dietary pattern to lower blood pressure in the general population,<sup>77–79</sup> data are inconsistent about its value in preventing the development of chronic hypertension after preeclampsia.<sup>80</sup> Future clinical trials could investigate the efficacy of dietary changes to prevent the development of CVD risk factors in women who have experienced an APO, particularly GD and hypertensive disorders of pregnancy.

### Physical Activity to Optimize Cardiovascular Health in Women of Reproductive Age and Pregnant Women

Maternal obesity is related in the short term to maternal difficulties with lactation (which as reviewed in this document has protective effects on cardiometabolic health) and in the long term with postpartum weight retention, type 2 diabetes, and increased risks of subsequent hypertensive disorders of pregnancy.<sup>81</sup> Health professional-led interventions may have greater efficacy at weight reduction than delivery by nonhealth professionals, and combined diet and exercise showed greater average weight reduction in a recent meta-analysis.<sup>82</sup> The American College of Obstetricians and Gynecologists recommends that women experiencing uncomplicated pregnancies regularly engage in moderate-intensity physical activity for at least 20 to 30 min/d on most or all days of the week.<sup>83</sup> Similarly, the 2008 Physical Activity Guidelines for Americans recommended 150 min/wk of moderate-intensity aerobic activity during pregnancy and postpartum spread throughout the week and continuation of vigorous activity in women who engaged in vigorous activity before pregnancy.<sup>84</sup>

## Other Lifestyle Factors

Maternal cigarette smoking is strongly discouraged in-trapartum and postpartum given its adverse effects on fetal short- and long-term health, including preterm birth, fetal growth restriction, low birth weight, sudden infant death syndrome, neurodevelopmental and behavioral problems, obesity, hypertension, type 2 diabetes, impaired lung function, and asthma.<sup>85</sup> These recommendations also have bearing on CVD reduction in women with smoking-related APOs because cigarette smoking is one of the most important modifiable risk factors in premenopausal women.<sup>86</sup> The topics of postpartum sleep and stress, including depression/anxiety, and later CVD in women have not been well studied but represent an important area for further research and a potential opportunity for future lifestyle recommendations unique to women in their childbearing years.

## RACIAL AND ETHNIC DISPARITIES IN PREGNANCY COMPLICATIONS AND CVD

Non-White women are at an increased risk for APOs that are associated with increased maternal CVD risk. In particular, non-Hispanic Black women are at an increased risk for hypertensive disorders of pregnancy, GD, and having a miscarriage, stillbirth, preterm delivery, or low-birth-weight infant compared with non-Hispanic White women.<sup>21,63,87–91</sup> Hispanic women are at an increased risk of preterm birth.<sup>90</sup> Asian women are at an increased risk of delivering a low-birth-weight or SGA infant and for developing GD.<sup>92</sup>

Black women have a higher incidence of preeclampsia than White women,<sup>87,93</sup> and preeclampsia is increasing more rapidly among Black women than among White women.<sup>87</sup> Clinical presentations<sup>87</sup> and outcomes are commonly more severe among women of color than among White women.<sup>94,95</sup> For instance, the case fatality rate for preeclampsia is 2.7 times higher among Black women than among White women (73.5 versus 27.4 deaths per 100 000 cases),<sup>93</sup> which may be attributable to inequalities in access to prenatal care and racial disparities in obesity and other prepregnancy risk factors.<sup>87,93</sup> However, the Bogalusa Heart Study suggested that only a small proportion of the racial disparities in pregnancy complications can be explained by differences in established risk factors between Black and White women.<sup>96</sup>

Pregnancy-related mortality rates between 2011 and 2013 were much higher in non-Hispanic Black women (43.5 deaths per 100 000 live births) than among non-Hispanic White women (12.7 deaths per 100 000 live births), Hispanic women (11.0 deaths per 100 000 live births), and women of other races (14.4

deaths per 100 000 live births).<sup>97</sup> This disparity may be related to structural, institutional, and systemic factors that disproportionally affect Black women in the United States, including lack of adequate health care insurance and access to care and other social determinants of health that have not been uniformly or fully accounted for in prior studies.<sup>87,98</sup>

Although it is known that non-Hispanic Black and Hispanic women are at increased risk for both pregnancy complications and CVD risk factors and events,<sup>87,99</sup> the relationships among these factors are poorly understood, largely because existing cohorts may have had limited follow-up and insufficiently diverse populations to fully study these associations. Indeed, most relevant study populations include 80% to 95% White women.<sup>26</sup> Only 18 of the 48 articles in a recent meta-analysis adjusted for race or ethnicity, and only 2 articles examined race as a potential effect modifier.<sup>26</sup> In 1 study of 77 701 women from the Women's Health Initiative, race was not shown to modify the relationship between pregnancy loss and CVD,<sup>100</sup> but Cirillo and Cohn<sup>101</sup> found a significant interaction by race ( $P=0.04$ ) in the association between gestational hypertension and CVD (HR, 1.7 [95% CI, 1.1–2.7] among Black women; HR, 0.92 [95% CI, 0.6–1.4] among non-Black women).

Studies such as the Black Women's Health Study, the largest cohort study of Black women in the United States, have the potential to examine the strength of these relationships among Black women.<sup>102</sup> Future studies are also needed in more diverse populations that are adequately powered to test whether race and ethnicity modify the association between pregnancy complications and CVD.

## ROLE OF LACTATION/BREASTFEEDING IN POSTPARTUM CVD PREVENTION IN WOMEN

Lactation is the second segment of the reproductive continuum and fosters recovery of maternal physiological systems to their preconception state. From this perspective, breastfeeding not only benefits the infant but also counterbalances and promotes recovery from the increased cardiometabolic stresses of normal pregnancy for the mother.<sup>103</sup>

Lactating women have more favorable cardiometabolic profiles, with lower fasting blood glucose, triglycerides, insulin resistance,<sup>104</sup> and blood pressure<sup>105</sup> and higher high-density lipoprotein cholesterol levels.<sup>106–108</sup> These favorable effects on maternal metabolism result from conserving maternal energy stores for milk production with minimal maternal weight loss (1–2 kg over a year).<sup>107,109–111</sup> The physiological effects of breastfeeding may reduce long-term cardiovascular risk and protect against breast and ovarian cancers.<sup>112,113</sup>

The CARDIA study (Coronary Artery Risk Development in Young Adults) of women 18 to 30 years of age found that longer breastfeeding was associated with higher high-density lipoprotein cholesterol levels<sup>109</sup> and less nonalcoholic fatty liver disease<sup>114</sup> and type 2 diabetes.<sup>115</sup> Longer-term studies found that breastfeeding was associated with a lower risk of early atherosclerosis<sup>111</sup> that was independent of lifestyle behaviors.<sup>115,116</sup> Lactation may lower CVD risk by lowering blood pressure and preventing hypertension.<sup>117,118</sup> The Black Women's Health Study found that longer breastfeeding duration was associated with lower risk of incident hypertension during middle age (40–49 years) but not at older ages (50–65 years).<sup>119,120</sup>

Studies of middle-aged and older women of Northern European ancestry found that a history of breastfeeding was associated with a 23% lower risk of myocardial infarction, coronary heart disease, subclinical CVD, and CVD events later in life.<sup>45,121–125</sup> Among women of childbearing age, prospective studies show somewhat stronger associations of breastfeeding with subsequent CVD events.<sup>126</sup>

The associations between breastfeeding duration and CVD mortality do not show consistent strength of associations or clear threshold or dose-response associations. Both ever breastfeeding and average breastfeeding duration per child (from 6–12 months) have been associated with lower risk of incident CVD hospitalization and mortality and incident ischemic heart disease or stroke compared with never breastfeeding.<sup>124,125,127</sup> Associations for lifetime breastfeeding duration with CVD mortality have been inconsistent.<sup>121,128</sup>

Evidence that breastfeeding influences CVD risk factors and outcomes among women who experience APOs has been much less available, particularly because APOs may diminish breastfeeding success, especially among Black women.<sup>120,129,130</sup> A cross-sectional study of women with any APOs evaluated breastfeeding status at 6 months after delivery and found more favorable cardiometabolic risk factors associated with current breastfeeding status or duration.<sup>131</sup> Another study of women with hypertensive disorders of pregnancy found that longer breastfeeding duration was associated with lower mean blood pressure at 9 months after delivery among women with previous gestational hypertension but not among women who were normotensive or developed preeclampsia.<sup>132</sup> Breastfeeding among women with a history of GD was associated with a lower incidence of subsequent type 2 diabetes, even after adjustment for weight change across the childbearing years.<sup>115,116,133</sup>

Breastfeeding during the first year postpartum may play an important role in reducing future risk of CVD outcomes in women, particularly for racial/ethnic groups susceptible to increased risk of APOs and CVD and who have lower prevalence rates of breastfeeding.

Well-designed longitudinal studies are needed to fill major research gaps related to lactation (breastfeeding history) and future CVD risk among women with APOs.

## PHARMACOTHERAPY

Whereas several studies have investigated use of pharmacotherapy to prevent the development of APOs, very few studies have focused on preventive CVD treatment specifically among women who have had an APO.


### Intrapartum APO Prevention

Low-dose aspirin is effective in reducing the development of preeclampsia and is recommended by the Society for Maternal-Fetal Medicine, the American College of Obstetricians and Gynecologists, and the US Preventive Task Force. Guidelines recommend low-dose aspirin for women at high risk of preeclampsia (those with a history of preeclampsia, advanced maternal age, chronic hypertension, etc), starting therapy between 12 and 28 weeks of gestation (optimally before 16 weeks) and continuing until delivery.<sup>134</sup> Data suggest a 30% reduction in preeclampsia onset after the institution of these recent guidelines.<sup>135</sup> A recent randomized study of low-dose aspirin initiated after 6 and up to 13 weeks of pregnancy in low- and middle-income countries demonstrated a modest reduction in preterm birth.<sup>136</sup> Whether these findings extend to high-income countries is not yet known but should be investigated comprehensively. Statin therapy may have a role in the prevention and treatment of preeclampsia during pregnancy. However, there are also concerns about the safety of statins during pregnancy, and no large clinical trials have proven efficacy.<sup>137,138</sup>

### Postpartum CVD Prevention

Metformin has been shown to reduce the incidence of type 2 diabetes in the general population and specifically in women with a history of GD. In the subgroup of woman with GD (n=350), the Diabetes Prevention Program found that metformin reduced diabetes incidence initially and by 35% in the subsequent 10 years after study randomization compared with placebo, which is similar to the effect of intensive lifestyle modification.<sup>139,140</sup> Whereas a UK trial found that metformin significantly reduced the frequency of preeclampsia and maternal weight gain,<sup>141,142</sup> the role of metformin for women with a history of preeclampsia remains unknown.

Whereas no clinical trials have specifically tested the use of statins for CVD prevention in women with a history of APOs, the 2018 American Heart Association cholesterol treatment guidelines classify GD, preeclampsia, preterm birth, or birth of an SGA infant as



**Figure.** Postpartum timing of cardiovascular disease risk factor (CVD RF) assessment and lifestyle counseling (LSC) in a woman with an adverse pregnancy outcome.

BMI indicates body mass index; BP, blood pressure; Ob-Gyn, obstetrician-gynecologist, and PCP, primary care provider.

risk enhancers that could be discussed with the patient when deciding whether to initiate statins for primary prevention of CVD.<sup>25</sup> Further studies in this area are needed to clarify the role of statins in primary CVD prevention among women with APO histories.

Regrettably, most large primary prevention randomized clinical trials did not collect data on participants' history of APOs, and it is unknown whether aspirin, statins, and metformin have a special role in prevention of CVD after APOs. A recent analysis in the observational California Teachers Study showed a benefit of aspirin for primary prevention of stroke in middle age in women with a history of hypertensive disorders of pregnancy.<sup>143</sup> This approach has not been tested in any interventional trials.

## HEALTH CARE SYSTEMS CHANGES TO IMPROVE TRANSITIONS IN CARE FROM OBSTETRICIANS/ GYNECOLOGISTS TO PRIMARY CARE

Delivery of health care is often segmented, and information about APOs has been the concern primarily of obstetricians only. However, the period after birth is a critical period for women to set the stage for the long-term health of themselves and of their families. The American College of Obstetricians and Gynecologists has recently called this period the fourth trimester to expand the focus beyond the traditional single postpartum visit.<sup>144</sup> Longer coverage for postpartum care such that the obstetrician/gynecologist or other health care providers can screen for the development of CVD

risk factors and provide adequate CVD risk prevention counseling, rather than simply offering a single postpartum visit, would improve long-term risk reduction for patients with APOs. Improved patient education is also necessary. Patients often do not know that having had a pregnancy complication might increase their future CVD risk.<sup>144</sup> Primary care physicians also may not appreciate the impact of APOs (including hypertensive disorders of pregnancy, preterm delivery, GD, SGA delivery, placental abruption, and pregnancy loss) on increased CVD risk, and these providers should be targeted for education<sup>144</sup> (Figure).

Another opportunity for improvement of postpartum care of women with APOs lies in more seamless communication between obstetrics providers and primary care physicians. Specifically, the separation of obstetric records from the general chart and inconsistencies in electronic record documentation may limit opportunities for CVD preventive care after an APO. This may occur even if the delivery occurred in the same institution where the woman receives primary care.<sup>145</sup> Improving transfer of information from obstetric providers to primary care clinicians within the permanent medical record and potentially harnessing electronic medical record information transfer and communication automation will ultimately improve the ability to deliver appropriate referrals and counseling.

Furthermore, current CVD risk assessment tools do not consider any female-specific risk factors, including APOs. The recent cholesterol treatment guidelines update did not address all APOs reviewed in this statement in terms of their recommended role as risk enhancers.<sup>25</sup> A recent international guideline statement from the United Kingdom



recommends, with a moderate quality of evidence, that women with hypertensive disorders of pregnancy be screened for thrombophilia subsequently and counseled to maintain a normal range of body mass index.<sup>146</sup> Aside from the American College of Cardiology/American Heart Association moderate-quality evidence–supported recommendations to evaluate and treat CVD risk factors among women with preeclampsia,<sup>24</sup> several other international societies have cited low- or very low-quality bodies of scientific evidence to make recommendations for women with hypertensive disorders of pregnancy to optimize their lifestyle for the aim of CVD prevention.<sup>147</sup>

Women with pregnancies complicated by hypertensive disorders of pregnancy, GD, placental abruption, and preterm delivery should be advised that these disorders are associated with a higher lifetime risk of CVD, and they should undergo CVD risk assessment.<sup>7,24</sup> Approaches could include a telephone education intervention<sup>148</sup> or use of other mobile coaching applications (apps) to enhance lifestyle change.<sup>149</sup> The postpartum period should be considered an opportunity to focus on lifestyle choices that optimize cardiovascular health, including weight management, smoking cessation, physical activity assessment, and nutritional counseling, particularly among those with pregnancy complications associated with increased CVD risk.<sup>145</sup> Currently, gaps in health insurance coverage may impede continuity of care among uninsured women. Indeed, insurance coverage by either Medicaid or the Children's Healthcare Insurance Program extends just 60 days postpartum (the latter having implications for offspring of a pregnancy and for pregnant adolescent girls, who themselves may be at a relatively higher CVD risk by way of early age at first pregnancy<sup>150</sup>). Legislation to continue coverage farther into the postpartum period, particularly for women with pregnancy complications, would provide better access to preventive care, as well as care of higher-risk individuals. Evaluation of CVD risk, with monitoring of blood pressure, lipids, fasting glucose, and body mass index, is recommended for women with a history of preeclampsia.<sup>10,24</sup> Evaluation for diabetes is recommended for women with a history of GD, including initial screening with an oral glucose tolerance test 4 to 12 weeks postpartum and further glycemic evaluation (glycohemoglobin, fasting glucose, or glucose tolerance test) every 1 to 3 years.<sup>147</sup>

Health care systems also need to improve follow-up for women with pregnancy complications. Consistent documentation of pregnancy complications in the medical record and coordination between obstetric and primary care providers are key. Postpartum transition clinics have proved to be an effective strategy.<sup>151</sup> Technology can also be used to improve cardiovascular health for women. Software algorithms can trigger patient education, referrals, and ambulatory blood pressure device monitoring. In a recent postpartum study

of remote blood pressure monitoring in women who had gestational hypertension or preeclampsia, 42% of women had antihypertensive medications initiated or titrated through the program, and 88% returned for the 6-week postpartum visit.<sup>152</sup> Mobile phone-based apps allow consumers to monitor and enhance their health. Medical technology research in the arena of prevention and intervention strategies for behavioral change holds great promise to improve care and potentially reduce health disparities because these strategies can reach most populations.<sup>76</sup> Specifically, app-based coaching for increasing physical activity and making dietary behavioral changes in pregnancy and postpartum is promising but requires further study to prove efficacy.<sup>153</sup>

## KNOWLEDGE GAPS AND CONSIDERATIONS

APOs provide a window into women's long-term cardiovascular risk and thus can provide an opportunity to help patients engage in CVD prevention. A larger body of evidence-based studies on the timing and specific components of lifestyle modification programs that are tailored to women in the postpartum setting and during her childbearing years are needed. Better education of patients and providers, coordination of care, female-specific risk prediction models, and testing of effective interventions to reduce long-term risk are urgently needed. Given the advent of the concept of the fourth trimester of pregnancy, the obstetrician/gynecologist or other health care provider may want to use this critical period to screen for the development of CVD risk factors and to provide adequate risk prevention counseling, rather than offering simply a single 6-week postpartum visit (Figure). This concept of a fourth trimester might also be used as public policy to extend the pregnancy-related insurance coverage for several months rather than a few weeks.

## SUMMARY OF FINDINGS AND IMPLICATIONS

1. APOs (hypertensive disorders of pregnancy, preterm delivery, GD, SGA delivery, placental abruption, and pregnancy loss) increase a woman's risk of developing CVD risk factor development and later CVD.
2. Consideration of APOs is essential when evaluating CVD risk in women, although their value in reclassifying risk may not yet be established.
3. More vigorous primordial prevention of CVD risk factors and primary prevention of CVD for women with a history of APOs.
4. Adopting a heart-healthy diet and increasing physical activity among women with APOs, starting in the postpartum setting and continuing

- across the life span, are important lifestyle interventions to decrease CVD risk.
5. Lactation and breastfeeding may lower a woman's later cardiometabolic risk.
  6. Black, Asian, and Hispanic women experience a higher proportion of APOs, with more severe clinical presentation and worse outcomes than in White women.
  7. More studies examining the association of APOs and CVD in non-White populations of women and health care implementation improvements can help to better address these health disparities.
  8. Future studies of aspirin, statins, and metformin may better inform our recommendations for pharmacotherapy in primary CVD prevention among women who have had an APO.
  9. Health care systems need to improve transitions of care for women with APOs and implement targeted strategies to reduce their long-term CVD risk.

ARTICLE INFORMATION

The American Heart Association makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel.

Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest.

This statement was approved by the American Heart Association Science Advisory and Coordinating Committee on December 10, 2020, and the American Heart Association Executive Committee on January 28, 2021. A copy of the document is available at <https://professional.heart.org/statements> by using either "Search for Guidelines & Statements" or the "Browse by Topic" area. To purchase additional reprints, call 215-356-2721 or email [Meredith.Edelman@wolterskluwer.com](mailto:Meredith.Edelman@wolterskluwer.com).

Supplemental materials are available with this article at <https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000961>.

The American Heart Association requests that this document be cited as follows: Parikh NI, Gonzalez JM, Anderson CAM, Judd SE, Rexrode KM, Hlatky MA, Gunderson EP, Stuart JJ, Vaidya D; on behalf of the American Heart Association Council on Epidemiology and Prevention; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Stroke Nursing; and the Stroke Council. Adverse pregnancy outcomes and cardiovascular disease risk: unique opportunities for cardiovascular disease prevention in women: a scientific statement from the American Heart Association. *Circulation*. 2021;143:e902–e916. doi: 10.1161/CIR.0000000000000961

The expert peer review of AHA-commissioned documents (eg, scientific statements, clinical practice guidelines, systematic reviews) is conducted by the AHA Office of Science Operations. For more on AHA statements and guidelines development, visit <https://professional.heart.org/statements>. Select the "Guidelines & Statements" drop-down menu, then click "Publication Development."

Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the American Heart Association. Instructions for obtaining permission are located at <https://www.heart.org/permissions>. A link to the "Copyright Permissions Request Form" appears in the second paragraph (<https://www.heart.org/en/about-us/statements-and-policies/copyright-request-form>).

Disclosures

Writing Group Disclosures

Writing group member	Employment	Research grant	Other research support	Speakers' bureau/honoraria	Expert witness	Ownership interest	Consultant/advisory board	Other
Nisha I. Parikh	University of California, San Francisco	None	None	None	None	None	None	None
Dhananjay Vaidya	Johns Hopkins University	American Heart Association (co-PI of a Core in AHA Go Red for Women grant) <sup>†</sup> NIDDK (co-PI of R01Sex Hormones and Cardiovascular Outcomes in Diabetes) <sup>†</sup>	None	None	None	None	None	None
Cheryl A.M. Anderson	University of California at San Diego	None	None	None	None	None	None	None
Juan M. Gonzalez	University of California, San Francisco	None	None	None	None	None	None	None
Erica P. Gunderson	Kaiser Permanente Northern California	AHA (clinical research coinvestigator)*; NHLBI (R01 PI Prenatal Blood Pressure Patterns) <sup>†</sup> ; NHLBI (R21 co-I Shared Antecedents to PTB)*; NHLBI (R56 Site PI GDM Cardiovascular Health) <sup>†</sup> ; NIDDK (R01 PI Pregnancy-Related Risk Factors and Glucose Tolerance in Women) <sup>†</sup> ; NIDDK (R01 PI Metabolites Preceding Progression to Diabetes) <sup>†</sup> ; NIDDK (R01 PI Fetal and Early Postnatal Factors on Child Metabolic Health) <sup>†</sup> ; NICHD (R01 co-I Maternal Inflammation During Pregnancy)*	None	None	None	None	None	None

(Continued)

## Writing Group Disclosures Continued

Writing group member	Employment	Research grant	Other research support	Speakers' bureau/honoraria	Expert witness	Ownership interest	Consultant/advisory board	Other
Mark A. Hlatky	Stanford University School of Medicine	NHLBI (R01 on pre-eclampsia and ASCVD) <sup>†</sup>	None	None	None	None	None	None
Suzanne E. Judd	University of Alabama at Birmingham School of Public Health	None	None	None	None	None	None	None
Kathryn M. Rexrode	Brigham and Women's Hospital, Harvard Medical School	None	None	None	None	None	None	None
Jennifer J. Stuart	Brigham and Women's Hospital and Harvard Medical School	None	None	None	None	None	None	None

This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be "significant" if (a) the person receives \$10 000 or more during any 12-month period, or 5% or more of the person's gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns \$10 000 or more of the fair market value of the entity. A relationship is considered to be "modest" if it is less than "significant" under the preceding definition.

\*Modest.

<sup>†</sup>Significant.

## Reviewer Disclosures

Reviewer	Employment	Research grant	Other research support	Speakers' bureau/honoraria	Expert witness	Ownership interest	Consultant/advisory board	Other
Eliza C. Miller	Columbia University	NIH/NINDS (K23NS107645: Career Development Award for research on maternal neurovascular unit dysfunction in preeclampsia) <sup>†</sup>	None	None	FOJP, Inc*	None	None	None
Pamela Ouyang	Johns Hopkins University	None	None	None	None	None	None	None
Nanette K. Wenger	Emory University School of Medicine	None	None	None	None	None	None	None

This table represents the relationships of reviewers that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all reviewers are required to complete and submit. A relationship is considered to be "significant" if (a) the person receives \$10 000 or more during any 12-month period, or 5% or more of the person's gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns \$10 000 or more of the fair market value of the entity. A relationship is considered to be "modest" if it is less than "significant" under the preceding definition.

\*Modest.

<sup>†</sup>Significant.

## REFERENCES

- Zeng Z, Liu F, Li S. Metabolic adaptations in pregnancy: a review. *Ann Nutr Metab*. 2017;70:59–65. doi: 10.1159/000459633
- Butte NF. Carbohydrate and lipid metabolism in pregnancy: normal compared with gestational diabetes mellitus. *Am J Clin Nutr*. 2000;71(suppl):1256S–1261S. doi: 10.1093/ajcn/71.5.1256S
- Gillespie SL, Porter K, Christian LM. Adaptation of the inflammatory immune response across pregnancy and postpartum in Black and White women. *J Reprod Immunol*. 2016;114:27–31. doi: 10.1016/j.jri.2016.02.001
- Bonamy AK, Parikh NI, Cnattingius S, Ludvigsson JF, Ingelsson E. Birth characteristics and subsequent risks of maternal cardiovascular disease: effects of gestational age and fetal growth. *Circulation*. 2011;124:2839–2846. doi: 10.1161/CIRCULATIONAHA.111.034884
- Sattar N, Greer IA. Pregnancy complications and maternal cardiovascular risk: opportunities for intervention and screening? *BMJ*. 2002;325:157–160. doi: 10.1136/bmj.325.7356.157
- Lane-Cordova AD, Khan SS, Grobman WA, Greenland P, Shah SJ. Long-term cardiovascular risks associated with adverse pregnancy outcomes: JACC review topic of the week. *J Am Coll Cardiol*. 2019;73:2106–2116. doi: 10.1016/j.jacc.2018.12.092
- Rich-Edwards JW, Fraser A, Lawlor DA, Catov JM. Pregnancy characteristics and women's future cardiovascular health: an underused opportunity to improve women's health? *Epidemiol Rev*. 2014;36:57–70. doi: 10.1093/epirev/mxt006
- Gestational hypertension and preeclampsia: ACOG Practice Bulletin, Number 222. *Obstet Gynecol*. 2020;135:e237–e260. doi: 10.1097/AOG.0000000000003891
- Wallis AB, Saftlas AF, Hsia J, Atrash HK. Secular trends in the rates of preeclampsia, eclampsia, and gestational hypertension, United States, 1987–2004. *Am J Hypertens*. 2008;21:521–526. doi: 10.1038/ajh.2008.20
- Hypertension in pregnancy: report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. *Obstet Gynecol*. 2013;122:1122–1131. doi: 10.1097/01.AOG.0000437382.03963.88
- Schlichting LE, Insaf TZ, Zaidi AN, Lui GK, Van Zutphen AR. Maternal comorbidities and complications of delivery in pregnant women with congenital heart disease. *J Am Coll Cardiol*. 2019;73:2181–2191. doi: 10.1016/j.jacc.2019.01.069

12. Centers for Disease Control (CDC). Gestational Diabetes. 2020. Accessed February 10, 2021. <https://www.cdc.gov/pregnancy/diabetes-gestational.html>
13. Ananth CV, Keyes KM, Hamilton A, Gissler M, Wu C, Liu S, Luque-Fernandez MA, Skjaerven R, Williams MA, Tikkanen M, et al. An international contrast of rates of placental abruption: an age-period-cohort analysis. *PLoS One*. 2015;10:e0125246. doi: 10.1371/journal.pone.0125246
14. Martin JA, Hamilton BE, Osterman MJK, Driscoll AK. Births: final data for 2018. *Natl Vital Stat Rep*. 2019;68:1–47.
15. Duryea EL, Hawkins JS, McIntire DD, Casey BM, Leveno KJ. A revised birth weight reference for the United States. *Obstet Gynecol*. 2014;124:16–22. doi: 10.1097/AOG.0000000000000345
16. Aris IM, Kleinman KP, Belfort MB, Kaimal A, Oken E. A 2017 US reference for singleton birth weight percentiles using obstetric estimates of gestation. *Pediatrics*. 2019;144:e20190076. doi: 10.1542/peds.2019-0076
17. Doty MS, Chen HY, Sibai BM, Chauhan SP. Maternal and neonatal morbidity associated with early term delivery of large-for-gestational-age but nonmacrosomic neonates. *Obstet Gynecol*. 2019;133:1160–1166. doi: 10.1097/AOG.0000000000000325
18. Nasiri K, Moodie EEM, Abenham HA. To what extent is the association between race/ethnicity and fetal growth restriction explained by adequacy of prenatal care? A mediation analysis of a retrospectively selected cohort. *Am J Epidemiol*. 2020;189:1360–1368. doi: 10.1093/aje/kwaa054
19. Suhag A, Berghella V. Intrauterine growth restriction (IUGR): etiology and diagnosis. *Curr Obstet Gynecol Rep*. 2013;2:102–111.
20. ACOG Practice Bulletin No. 204: fetal growth restriction. *Obstet Gynecol*. 2019;133:e97–e109. doi: 10.1097/AOG.00000000000003070
21. ACOG Practice Bulletin No. 190: gestational diabetes mellitus. *Obstet Gynecol*. 2018;131:e49–e64. doi: 10.1097/AOG.00000000000002501
22. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. *BMJ*. 2005;330:565. doi: 10.1136/bmj.38380.674340.E0
23. Parikh NI, Laria B, Nah G, Singhal M, Vittinghoff E, Vieten C, Stotland N, Coleman-Phox K, Adler N, Albert MA, et al. Cardiovascular disease-related pregnancy complications are associated with increased maternal levels and trajectories of cardiovascular disease biomarkers during and after pregnancy. *J Womens Health (Larchmt)*. 2020;29:1283–1291. doi: 10.1089/jwh.2018.7560
24. Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, Newby LK, Piña IL, Roger VL, Shaw LJ, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women—2011 update: a guideline from the American Heart Association [published corrections appear in *Circulation*. 2011;123:e624 and *Circulation*. 2011;124:e427]. *Circulation*. 2011;123:1243–1262. doi: 10.1161/CIR.0b013e31820faaf8
25. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APHA/ASPC/NLA/PCNA guideline on the management of blood cholesterol [published correction appears in *Circulation*. 2019;139:e1182–e1186]. *Circulation*. 2019;139:e1082–e1143. doi: 10.1161/CIR.0000000000000625
26. Grandi SM, Filion KB, Yoon S, Ayele HT, Doyle CM, Hutcheon JA, Smith GN, Gore GC, Ray JG, Nerenberg K, et al. Cardiovascular disease-related morbidity and mortality in women with a history of pregnancy complications. *Circulation*. 2019;139:1069–1079. doi: 10.1161/CIRCULATIONAHA.118.036748
27. Canoy D, Cairns BJ, Balkwill A, Wright FL, Khalil A, Beral V, Green J, Reeves G; Million Women Study Collaborators. Hypertension in pregnancy and risk of coronary heart disease and stroke: a prospective study in a large UK cohort. *Int J Cardiol*. 2016;222:1012–1018. doi: 10.1016/j.ijcard.2016.07.170
28. Grandi SM, Reynier P, Platt RW, Basso O, Filion KB. The timing of onset of hypertensive disorders in pregnancy and the risk of incident hypertension and cardiovascular disease. *Int J Cardiol*. 2018;270:273–275. doi: 10.1016/j.ijcard.2018.06.059
29. Heida KY, Bots ML, de Groot CJ, van Dunné FM, Hammoud NM, Hoek A, Laven JS, Maas AH, Roeters van Lennep JE, Velthuis BK, et al. Cardiovascular risk management after reproductive and pregnancy-related disorders: a Dutch multidisciplinary evidence-based guideline. *Eur J Prev Cardiol*. 2016;23:1863–1879. doi: 10.1177/2047487316659573
30. Markovitz AR, Stuart JJ, Horn J, Williams PL, Rimm EB, Missmer SA, Tanz LJ, Haug EB, Fraser A, Timpka S, et al. Does pregnancy complication history improve cardiovascular disease risk prediction? Findings from the HUNT study in Norway. *Eur Heart J*. 2019;40:1113–1120. doi: 10.1093/eurheartj/ehy863
31. Riise HK, Sulo G, Tell GS, Igland J, Nygard O, Vollset SE, Iversen AC, Austgulen R, Daltveit AK. Incident coronary heart disease after preeclampsia: a rule of reduced fetal growth, preterm delivery, and parity. *J Am Heart Assoc*. 2017;6:e004158. doi: 10.1161/JAHA.116.004158
32. Riise HKR, Sulo G, Tell GS, Igland J, Egeland G, Nygard O, Selmer R, Iversen AC, Daltveit AK. Hypertensive pregnancy disorders increase the risk of maternal cardiovascular disease after adjustment for cardiovascular risk factors. *Int J Cardiol*. 2019;282:81–87. doi: 10.1016/j.ijcard.2019.01.097
33. Riise HKR, Sulo G, Tell GS, Igland J, Nygard O, Iversen AC, Daltveit AK. Association between gestational hypertension and risk of cardiovascular disease among 617 589 Norwegian women. *J Am Heart Assoc*. 2018;7:e008337. doi: 10.1161/JAHA.117.008337
34. Stuart JJ, Tanz LJ, Cook NR, Spiegelman D, Missmer SA, Rimm EB, Rexrode KM, Mukamal KJ, Rich-Edwards JW. Hypertensive disorders of pregnancy and 10-year cardiovascular risk prediction. *J Am Coll Cardiol*. 2018;72:1252–1263. doi: 10.1016/j.jacc.2018.05.077
35. Theilen LH, Meeks H, Fraser A, Esplin MS, Smith KR, Varner MW. Long-term mortality risk and life expectancy following recurrent hypertensive disease of pregnancy. *Am J Obstet Gynecol*. 2018;219:107.e1–107.e6. doi: 10.1016/j.ajog.2018.04.002
36. Timpka S, Fraser A, Schyman T, Stuart JJ, Åsvold BO, Mogren I, Franks PW, Rich-Edwards JW. The value of pregnancy complication history for 10-year cardiovascular disease risk prediction in middle-aged women. *Eur J Epidemiol*. 2018;33:1003–1010. doi: 10.1007/s10654-018-0429-1
37. Wu P, Haththotuwa R, Kwok CS, Babu A, Kotronias RA, Rushton C, Zaman A, Fryer AA, Kadam U, Chew-Graham CA, et al. Preeclampsia and future cardiovascular health: a systematic review and meta-analysis. *Circ Cardiovasc Qual Outcomes*. 2017;10:e003497. doi: 10.1161/CIRCOUTCOMES.116.003497
38. Kramer CK, Campbell S, Retnakaran R. Gestational diabetes and the risk of cardiovascular disease in women: a systematic review and meta-analysis. *Diabetologia*. 2019;62:905–914. doi: 10.1007/s00125-019-4840-2
39. Tanz LJ, Stuart JJ, Williams PL, Missmer SA, Rimm EB, James-Todd TM, Rich-Edwards JW. Preterm delivery and maternal cardiovascular disease risk factors: the Nurses' Health Study II. *J Womens Health (Larchmt)*. 2019;28:677–685. doi: 10.1089/jwh.2018.7150
40. Wu P, Gulati M, Kwok CS, Wong CW, Narain A, O'Brien S, Chew-Graham CA, Verma G, Kadam UT, Mamas MA. Preterm delivery and future risk of maternal cardiovascular disease: a systematic review and meta-analysis. *J Am Heart Assoc*. 2018;7:e007809. doi: 10.1161/JAHA.117.007809
41. Arnold L, Hoy W, Wang Z. Low birthweight increases risk for cardiovascular disease hospitalisations in a remote Indigenous Australian community: a prospective cohort study. *Aust NZ J Public Health*. 2016;40(suppl 1):S102–S106. doi: 10.1111/1753-6405.12426
42. Ngo AD, Roberts CL, Chen JS, Figtree G. Delivery of a small-for-gestational-age infant and risk of maternal cardiovascular disease: a population-based record linkage study. *Heart Lung Circ*. 2015;24:696–704. doi: 10.1016/j.hlc.2015.01.004
43. Morken NH, Halland F, DeRoo LA, Wilcox AJ, Skjaerven R. Offspring birthweight by gestational age and parental cardiovascular mortality: a population-based cohort study. *BJOG*. 2018;125:336–341. doi: 10.1111/1471-0528.14522
44. Hall PS, Nah G, Vittinghoff E, Parker DR, Manson JE, Howard BV, Sarto GE, Gass ML, Sealy-Jefferson SM, Salmoirago-Blotcher E, et al. Relation of pregnancy loss to risk of cardiovascular disease in parous postmenopausal women (from the Women's Health Initiative). *Am J Cardiol*. 2019;123:1620–1625. doi: 10.1016/j.amjcard.2019.02.012
45. Parikh NI, Jeppson RP, Berger JS, Eaton CB, Kroenke CH, LeBlanc ES, Lewis CE, Loucks EB, Parker DR, Rillamas-Sun E, et al. Reproductive risk factors and coronary heart disease in the Women's Health Initiative observational study. *Circulation*. 2016;133:2149–2158. doi: 10.1161/CIRCULATIONAHA.115.017854
46. Peters SA, Woodward M. Women's reproductive factors and incident cardiovascular disease in the UK Biobank. *Heart*. 2018;104:1069–1075. doi: 10.1136/heartjnl-2017-312289
47. Tobias DK, Hu FB, Forman JP, Chavarro J, Zhang C. Increased risk of hypertension after gestational diabetes mellitus: findings from a large prospective cohort study. *Diabetes Care*. 2011;34:1582–1584. doi: 10.2337/dc11-0268
48. Parikh NI, Norberg M, Ingelsson E, Cnattingius S, Vasan RS, Domellöf M, Jansson JH, Edstedt Bonamy AK. Association of pregnancy complications and characteristics with future risk of elevated blood pressure: the



- Västerbotten Intervention Program. *Hypertension*. 2017;69:475–483. doi: 10.1161/HYPERTENSIONAHA.116.08121
49. Retnakaran R, Qi Y, Connelly PW, Sermer M, Hanley AJ, Zinman B. The graded relationship between glucose tolerance status in pregnancy and postpartum levels of low-density-lipoprotein cholesterol and apolipoprotein B in young women: implications for future cardiovascular risk. *J Clin Endocrinol Metab*. 2010;95:4345–4353. doi: 10.1210/jc.2010-0361
  50. Kim C, Cheng YJ, Beckles GL. Cardiovascular disease risk profiles in women with histories of gestational diabetes but without current diabetes. *Obstet Gynecol*. 2008;112:875–883. doi: 10.1097/AOG.0b013e31818638b5
  51. Fraser A, Nelson SM, Macdonald-Wallis C, Cherry L, Butler E, Sattar N, Lawlor DA. Associations of pregnancy complications with calculated cardiovascular disease risk and cardiovascular risk factors in middle age: the Avon Longitudinal Study of Parents and Children. *Circulation*. 2012;125:1367–1380. doi: 10.1161/CIRCULATIONAHA.111.044784
  52. Catov JM, Althouse AD, Lewis CE, Harville EW, Gunderson EP. Preterm delivery and metabolic syndrome in women followed from prepregnancy through 25 years later. *Obstet Gynecol*. 2016;127:1127–1134. doi: 10.1097/AOG.0000000000001434
  53. Cortes YI, Catov JM, Brooks M, Harlow SD, Isasi CR, Jackson EA, Matthews KA, Thurston RC, Barinas-Mitchell E. History of adverse pregnancy outcomes, blood pressure, and subclinical vascular measures in late midlife: SWAN (Study of Women's Health Across the Nation). *J Am Heart Assoc*. 2017;7:e007138. doi: 10.1161/JAHA.117.007138
  54. Haas DM, Parker CB, Marsh DJ, Grobman WA, Ehrenthal DB, Greenland P, Bairey Merz CN, Pemberton VL, Silver RM, Barnes S, et al; NHLBI NuMoM2b Heart Health Study. Association of adverse pregnancy outcomes with hypertension 2 to 7 years postpartum. *J Am Heart Assoc*. 2019;8:e013092. doi: 10.1161/JAHA.119.013092
  55. Catov JM, Dodge R, Yamal JM, Roberts JM, Piller LB, Ness RB. Prior preterm or small-for-gestational-age birth related to maternal metabolic syndrome. *Obstet Gynecol*. 2011;117(pt 1):225–232. doi: 10.1097/AOG.0b013e3182075626
  56. Catov JM, Lewis CE, Lee M, Wellons MF, Gunderson EP. Preterm birth and future maternal blood pressure, inflammation, and intimal-medial thickness: the CARDIA study. *Hypertension*. 2013;61:641–646. doi: 10.1161/HYPERTENSIONAHA.111.00143
  57. Ranthe MF, Andersen EA, Wohlfahrt J, Bundgaard H, Melbye M, Boyd HA. Pregnancy loss and later risk of atherosclerotic disease. *Circulation*. 2013;127:1775–1782. doi: 10.1161/CIRCULATIONAHA.112.000285
  58. Horn J, Tanz LJ, Stuart JJ, Markovitz AR, Skurnik G, Rimm EB, Missmer SA, Rich-Edwards JW. Early or late pregnancy loss and development of clinical cardiovascular disease risk factors: a prospective cohort study. *BJOG*. 2019;126:33–42. doi: 10.1111/1471-0528.15452
  59. Brown MC, Best KE, Pearce MS, Waugh J, Robson SC, Bell R. Cardiovascular disease risk in women with pre-eclampsia: systematic review and meta-analysis. *Eur J Epidemiol*. 2013;28:1–19. doi: 10.1007/s10654-013-9762-6
  60. Wang Z, Wang Z, Wang L, Qiu M, Wang Y, Hou X, Guo Z, Wang B. Hypertensive disorders during pregnancy and risk of type 2 diabetes in later life: a systematic review and meta-analysis. *Endocrine*. 2017;55:809–821. doi: 10.1007/s12020-016-1075-6
  61. Hermes W, Ket JC, van Pampus MG, Franx A, Veenendaal MV, Kolster C, Tamsma JT, Bloemenkamp KW, Ponjee G, van der Hout E, et al. Biochemical cardiovascular risk factors after hypertensive pregnancy disorders: a systematic review and meta-analysis. *Obstet Gynecol Surv*. 2012;67:793–809. doi: 10.1097/OGX.0b013e31827682fc
  62. Vounzoulaki E, Khunti K, Abner SC, Tan BK, Davies MJ, Gillies CL. Progression to type 2 diabetes in women with a known history of gestational diabetes: systematic review and meta-analysis. *BMJ*. 2020;369:m1361. doi: 10.1136/bmj.m1361
  63. Groenhouf TKJ, Zoet GA, Franx A, Gansevoort RT, Bots ML, Groen H, Lely AT, on behalf of the PREVEND Group. Trajectory of cardiovascular risk factors after hypertensive disorders of pregnancy. *Hypertension*. 2019;73:171–178. doi: 10.1161/HYPERTENSIONAHA.118.11726
  64. Rayanagoudar G, Hashi AA, Zamora J, Khan KS, Hitman GA, Thangaratnam S. Quantification of the type 2 diabetes risk in women with gestational diabetes: a systematic review and meta-analysis of 95,750 women. *Diabetologia*. 2016;59:1403–1411. doi: 10.1007/s00125-016-3927-2
  65. Lang AY, Boyle JA, Fitzgerald GL, Teede H, Mazza D, Moran LJ, Harrison C. Optimizing preconception health in women of reproductive age. *Minerva Ginecol*. 2018;70:99–119. doi: 10.23736/S0026-4784.17.04140-5
  66. Stang J, Huffman LG. Position of the Academy of Nutrition and Dietetics: obesity, reproduction, and pregnancy outcomes. *J Acad Nutr Diet*. 2016;116:677–691. doi: 10.1016/j.jand.2016.01.008
  67. Stephenson J, Heslehurst N, Hall J, Schoenaker DAJM, Hutchinson J, Cade JE, Poston L, Barrett G, Crozier SR, Barker M, et al. Before the beginning: nutrition and lifestyle in the preconception period and its importance for future health. *Lancet*. 2018;391:1830–1841. doi: 10.1016/S0140-6736(18)30311-8
  68. Grieger JA, Grzeskowiak LE, Clifton VL. Preconception dietary patterns in human pregnancies are associated with preterm delivery. *J Nutr*. 2014;144:1075–1080. doi: 10.3945/jn.114.190686
  69. Courtney AU, O'Brien EC, Crowley RK, Geraghty AA, Brady MB, Kilbane MT, Twomey PJ, McKenna MJ, McAuliffe FM. DASH (Dietary Approaches to Stop Hypertension) dietary pattern and maternal blood pressure in pregnancy. *J Hum Nutr Diet*. 2020;33:686–697. doi: 10.1111/jhn.12744
  70. Asemi Z, Samimi M, Tabassi Z, Esmailzadeh A. The effect of DASH diet on pregnancy outcomes in gestational diabetes: a randomized controlled clinical trial. *Eur J Clin Nutr*. 2014;68:490–495. doi: 10.1038/ejcn.2013.296
  71. Martin CL, Sotres-Alvarez D, Siega-Riz AM. Maternal dietary patterns during the second trimester are associated with preterm birth. *J Nutr*. 2015;145:1857–1864. doi: 10.3945/jn.115.212019
  72. Institute of Medicine (US) Subcommittee on Interpretation and Uses of Dietary Reference Intakes. *Dietary Reference Intakes: The Essential Guide to Nutrient Requirements*. National Academies Press; 2006.
  73. Institute of Medicine. *Dietary Reference Intakes: The Essential Guide to Nutrient Requirements*. National Academies Press; 2006.
  74. Mijatovic-Vukas J, Capling L, Cheng S, Stamatakis E, Louie J, Cheung NW, Markovic T, Ross G, Senior A, Brand-Miller JC, et al. Associations of diet and physical activity with risk for gestational diabetes mellitus: a systematic review and meta-analysis. *Nutrients*. 2018;10:698. doi: 10.3390/nu10060698
  75. Bellamy L, Casas JP, Hingorani AD, Williams D. Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. *Lancet*. 2009;373:1773–1779. doi: 10.1016/S0140-6736(09)60731-5
  76. Brown SD, Ehrlich SF, Kubo A, Tsai AL, Hedderson MM, Quesenberry CP Jr, Ferrara A. Lifestyle behaviors and ethnic identity among diverse women at high risk for type 2 diabetes. *Soc Sci Med*. 2016;160:87–93. doi: 10.1016/j.socscimed.2016.05.024
  77. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, Bray GA, Vogt TM, Cutler JA, Windhauser MM, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. *N Engl J Med*. 1997;336:1117–1124. doi: 10.1056/NEJM199704173361601
  78. Appel LJ, Brands MW, Daniels SR, Karanja N, Elmer PJ, Sacks FM. Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association. *Hypertension*. 2006;47:296–308. doi: 10.1161/01.HYP.0000202568.01167.B6
  79. Eckel RH, Jakicic JM, Ard JD, de Jesus JM, Houston Miller N, Hubbard VS, Lee IM, Lichtenstein AH, Loria CM, Millen BE, et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published corrections appear in *Circulation*. 2014;129:S100–S101 and *Circulation*. 2015;131:e326]. *Circulation*. 2014;129(suppl 2):S76–S99. doi: 10.1161/01.cir.0000437740.48606.d1
  80. Eshriqui I, Vilela AA, Rebelo F, Farias DR, Castro MB, Kac G. Gestational dietary patterns are not associated with blood pressure changes during pregnancy and early postpartum in a Brazilian prospective cohort. *Eur J Nutr*. 2016;55:21–32. doi: 10.1007/s00394-014-0819-4
  81. Farpour-Lambert NJ, Ellis LJ, Martinez de Tejada B, Scott C. Obesity and weight gain in pregnancy and postpartum: an evidence review of lifestyle interventions to inform maternal and child health policies. *Front Endocrinol (Lausanne)*. 2018;9:546. doi: 10.3389/fendo.2018.00546
  82. Lim S, Liang X, Hill B, Teede H, Moran LJ, O'Reilly S. A systematic review and meta-analysis of intervention characteristics in postpartum weight management using the TiDiEr framework: a summary of evidence to inform implementation. *Obes Rev*. 2019;20:1045–1056. doi: 10.1111/obr.12846
  83. ACOG Committee Opinion No. 650: physical activity and exercise during pregnancy and the postpartum period. *Obstet Gynecol*. 2015;126:e135–e142. doi: 10.1097/AOG.0000000000001214
  84. US Department of Health and Human Services. *Physical Activity Guidelines for Americans, 2nd edition*. Washington, DC: U.S. Department of Health and Human Services; 2018.
  85. Banderali G, Martelli A, Landi M, Moretti F, Betti F, Radaelli G, Lassandro C, Verduci E. Short and long term health effects of parental tobacco smoking during pregnancy and lactation: a descriptive review. *J Transl Med*. 2015;13:327. doi: 10.1186/s12967-015-0690-y

86. Appelman Y, van Rijn BB, Ten Haaf ME, Boersma E, Peters SA. Sex differences in cardiovascular risk factors and disease prevention. *Atherosclerosis*. 2015;241:211–218. doi: 10.1016/j.atherosclerosis.2015.01.027
87. Breathett K, Muhlestein D, Foraker R, Gulati M. Differences in preeclampsia rates between African American and Caucasian women: trends from the National Hospital Discharge Survey. *J Womens Health (Larchmt)*. 2014;23:886–893. doi: 10.1089/jwh.2014.4749
88. ACOG Practice Bulletin No. 102: management of stillbirth. *Obstet Gynecol*. 2009;113:748–761. doi: 10.1097/AOG.0b013e31819e9ee2
89. ACOG Practice Bulletin No. 202: gestational hypertension and preeclampsia. *Obstet Gynecol*. 2019;133:e1–e25. doi: 10.1097/AOG.0000000000003018
90. Borrell LN, Rodriguez-Alvarez E, Savitz DA, Baquero MC. Parental race/ethnicity and adverse birth outcomes in New York City: 2000–2010. *Am J Public Health*. 2016;106:1491–1497. doi: 10.2105/AJPH.2016.303242
91. Mukherjee S, Velez Edwards DR, Baird DD, Savitz DA, Hartmann KE. Risk of miscarriage among Black women and White women in a U.S. prospective cohort study. *Am J Epidemiol*. 2013;177:1271–1278. doi: 10.1093/aje/kws393
92. Hedderson M, Ehrlich S, Sridhar S, Darbinian J, Moore S, Ferrara A. Racial/ethnic disparities in the prevalence of gestational diabetes mellitus by BMI. *Diabetes Care*. 2012;35:1492–1498. doi: 10.2337/dc11-2267
93. US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, Curry SJ, Barry MJ, Davidson KW, Doubeni CA, Epling JW Jr, Kemper AR, Krist AH, Kurth AE, et al. Screening for preeclampsia: US Preventive Services Task Force recommendation statement. *JAMA*. 2017;317:1661–1667.
94. Shahul S, Tung A, Minhaj M, Nizamuddin J, Wenger J, Mahmood E, Mueller A, Shaefi S, Scavone B, Kociol RD, et al. Racial disparities in comorbidities, complications, and maternal and fetal outcomes in women with preeclampsia/eclampsia. *Hypertens Pregnancy*. 2015;34:506–515. doi: 10.3109/10641955.2015.1090581
95. Goodwin AA, Mercer BM. Does maternal race or ethnicity affect the expression of severe preeclampsia? *Am J Obstet Gynecol*. 2005;193(pt 2):973–978. doi: 10.1016/j.ajog.2005.05.047
96. Harville EW, Myers L, Shu T, Wallace ME, Bazzano LA. Pre-pregnancy cardiovascular risk factors and racial disparities in birth outcomes: the Bogalusa Heart Study. *BMC Pregnancy Childbirth*. 2018;18:339. doi: 10.1186/s12884-018-1959-y
97. Creanga AA, Syverson C, Seed K, Callaghan WM. Pregnancy-related mortality in the United States, 2011–2013. *Obstet Gynecol*. 2017;130:366–373. doi: 10.1097/AOG.0000000000002114
98. Njoroge JN, Parikh NI. Understanding health disparities in cardiovascular diseases in pregnancy among Black women: prevalence, preventive care, and peripartum support networks. *Curr Cardiovasc Risk Rep*. 2020;8:1–8.
99. Caleyachetty R, Echouffo-Tcheugui JB, Muennig P, Zhu W, Muntner P, Shimbo D. Association between cumulative social risk and ideal cardiovascular health in US adults: NHANES 1999–2006. *Int J Cardiol*. 2015;191:296–300. doi: 10.1016/j.ijcard.2015.05.007
100. Parker DR, Lu B, Sands-Lincoln M, Kroenke CH, Lee CC, O'Sullivan M, Park HL, Parikh N, Schenken RS, Eaton CB. Risk of cardiovascular disease among postmenopausal women with prior pregnancy loss: the Women's Health Initiative. *Ann Fam Med*. 2014;12:302–309. doi: 10.1370/afm.1668
101. Cirillo PM, Cohn BA. Pregnancy complications and cardiovascular disease death: 50-year follow-up of the Child Health and Development Studies pregnancy cohort. *Circulation*. 2015;132:1234–1242. doi: 10.1161/CIRCULATIONAHA.113.003901
102. Rosenberg L, Adams-Campbell L, Palmer JR. The Black Women's Health Study: a follow-up study for causes and preventions of illness. *J Am Med Womens Assoc (1972)*. 1995;50:56–58.
103. Stuebe AM, Rich-Edwards JW. The reset hypothesis: lactation and maternal metabolism. *Am J Perinatol*. 2009;26:81–88. doi: 10.1055/s-0028-1103034
104. Tigas S, Sunehag A, Haymond MW. Metabolic adaptation to feeding and fasting during lactation in humans. *J Clin Endocrinol Metab*. 2002;87:302–307. doi: 10.1210/jcem.87.1.8178
105. Wiklund P, Xu L, Lyytikäinen A, Saltevo J, Wang Q, Völgyi E, Munukka E, Cheng S, Alen M, Keinänen-Kiukkaanniemi S, et al. Prolonged breastfeeding protects mothers from later-life obesity and related cardiometabolic disorders. *Public Health Nutr*. 2012;15:67–74. doi: 10.1017/S1368980011002102
106. Gunderson EP, Crites Y, Chiang V, Walton D, Azevedo RA, Fox G, Elmasian C, Young S, Salvador N, Lum M, et al. Influence of breastfeeding during the postpartum oral glucose tolerance test on plasma glucose and insulin. *Obstet Gynecol*. 2012;120:136–143. doi: 10.1097/AOG.0b013e31825b993d
107. Gunderson EP, Kim C, Quesenberry CP Jr, Marcovina S, Walton D, Azevedo RA, Fox G, Elmasian C, Young S, Salvador N, et al. Lactation intensity and fasting plasma lipids, lipoproteins, non-esterified free fatty acids, leptin and adiponectin in postpartum women with recent gestational diabetes mellitus: the SWIFT cohort. *Metabolism*. 2014;63:941–950. doi: 10.1016/j.metabol.2014.04.006
108. Nguyen B, Jin K, Ding D. Breastfeeding and maternal cardiovascular risk factors and outcomes: a systematic review. *PLoS One*. 2017;12:e0187923. doi: 10.1371/journal.pone.0187923
109. Gunderson EP, Lewis CE, Wei GS, Whitmer RA, Quesenberry CP, Sidney S. Lactation and changes in maternal metabolic risk factors. *Obstet Gynecol*. 2007;109:729–738. doi: 10.1097/01.AOG.0000252831.06695.03
110. Gunderson EP, Hedderson MM, Chiang V, Crites Y, Walton D, Azevedo RA, Fox G, Elmasian C, Young S, Salvador N, et al. Lactation intensity and postpartum maternal glucose tolerance and insulin resistance in women with recent GDM: the SWIFT cohort. *Diabetes Care*. 2012;35:50–56. doi: 10.2337/dc11-1409
111. Gunderson EP, Quesenberry CP Jr, Ning X, Jacobs DR Jr, Gross M, Goff DC Jr, Pletcher MJ, Lewis CE. Lactation duration and midlife atherosclerosis. *Obstet Gynecol*. 2015;126:381–390. doi: 10.1097/AOG.0000000000000919
112. Bartick MC, Stuebe AM, Schwarz EB, Luongo C, Reinhold AG, Foster EM. Cost analysis of maternal disease associated with suboptimal breastfeeding. *Obstet Gynecol*. 2013;122:111–119. doi: 10.1097/AOG.0b013e318297a047
113. Faupel-Badger JM, Arcaro KF, Balkam JJ, Eliassen AH, Hassiotou F, Lebrilla CB, Michels KB, Palmer JR, Schedin P, Stuebe AM, et al. Postpartum remodeling, lactation, and breast cancer risk: summary of a National Cancer Institute-sponsored workshop. *J Natl Cancer Inst*. 2013;105:166–174. doi: 10.1093/jnci/djs505
114. Ajmera VH, Terrault NA, VanWagner LB, Sarkar M, Lewis CE, Carr JJ, Gunderson EP. Longer lactation duration is associated with decreased prevalence of non-alcoholic fatty liver disease in women. *J Hepatol*. 2019;70:126–132. doi: 10.1016/j.jhep.2018.09.013
115. Gunderson EP, Lewis CE, Lin Y, Sorel M, Gross M, Sidney S, Jacobs DR Jr, Shikany JM, Quesenberry CP Jr. Lactation duration and progression to diabetes in women across the childbearing years: the 30-year CARDIA study. *JAMA Intern Med*. 2018;178:328–337. doi: 10.1001/jamainternmed.2017.7978
116. Gunderson EP, Jacobs DR Jr, Chiang V, Lewis CE, Feng J, Quesenberry CP Jr, Sidney S. Duration of lactation and incidence of the metabolic syndrome in women of reproductive age according to gestational diabetes mellitus status: a 20-year prospective study in CARDIA (Coronary Artery Risk Development in Young Adults). *Diabetes*. 2010;59:495–504. doi: 10.2337/db09-1197
117. Bonifacio E, Schwartz EB, Jun H, Wessel CB, Corbelli JA. Effect of lactation on maternal hypertension: a systematic review. *Breastfeed Med*. 2018;13:578–588. doi: 10.1089/bfm.2018.0108
118. Qu G, Wang L, Tang X, Wu W, Sun Y. Association between duration of breastfeeding and maternal hypertension: a systematic review and meta-analysis. *Breastfeed Med*. 2018;13:318–326. doi: 10.1089/bfm.2017.0180
119. Lee SY, Kim MT, Jee SH, Yang HP. Does long-term lactation protect premenopausal women against hypertension risk? A Korean women's cohort study. *Prev Med*. 2005;41:433–438. doi: 10.1016/j.ypmed.2004.11.025
120. Chetwynd EM, Stuebe AM, Rosenberg L, Troester M, Rowley D, Palmer JR. Cumulative lactation and onset of hypertension in African-American women. *Am J Epidemiol*. 2017;186:927–934. doi: 10.1093/aje/kwx163
121. Stuebe AM, Michels KB, Willett WC, Manson JE, Rexrode K, Rich-Edwards JW. Duration of lactation and incidence of myocardial infarction in middle to late adulthood. *Am J Obstet Gynecol*. 2009;200:138.e1–138.e8. doi: 10.1016/j.ajog.2008.10.001
122. Schwarz EB, McClure CK, Tepper PG, Thurston R, Janssen I, Matthews KA, Sutton-Tyrrell K. Lactation and maternal measures of subclinical cardiovascular disease. *Obstet Gynecol*. 2010;115:41–48. doi: 10.1097/AOG.0b013e3181c5512a
123. Schwarz EB, Ray RM, Stuebe AM, Allison MA, Ness RB, Freiberg MS, Cauley JA. Duration of lactation and risk factors for maternal cardiovascular disease. *Obstet Gynecol*. 2009;113:974–982. doi: 10.1097/01.AOG.0000346884.67796.ca

124. Peters SAE, Yang L, Guo Y, Chen Y, Bian Z, Du J, Yang J, Li S, Li L, Woodward M, et al. Breastfeeding and the risk of maternal cardiovascular disease: a prospective study of 300 000 Chinese women. *J Am Heart Assoc*. 2017;6:e006081. doi: 10.1161/JAHA.117.006081
125. Peters SA, van der Schouw YT, Wood AM, Sweeting MJ, Moons KG, Weiderpass E, Arriola L, Benetou V, Boeing H, Bonnet F, et al. Parity, breastfeeding and risk of coronary heart disease: a pan-European case-cohort study. *Eur J Prev Cardiol*. 2016;23:1755–1765. doi: 10.1177/2047487316658571
126. Kirkegaard H, Bliddal M, Støvring H, Rasmussen KM, Gunderson EP, Køber L, Sørensen TIA, Nohr EA. Breastfeeding and later maternal risk of hypertension and cardiovascular disease: the role of overall and abdominal obesity. *Prev Med*. 2018;114:140–148. doi: 10.1016/j.ypmed.2018.06.014
127. Nguyen B, Gale J, Nassar N, Bauman A, Joshy G, Ding D. Breastfeeding and cardiovascular disease hospitalization and mortality in parous women: evidence from a large Australian cohort study. *J Am Heart Assoc*. 2019;8:e011056. doi: 10.1161/JAHA.118.011056
128. Natland Fagerhaug T, Forsmo S, Jacobsen GW, Midtthjell K, Andersen LF, Ivar Lund Nilsen T. A prospective population-based cohort study of lactation and cardiovascular disease mortality: the HUNT study. *BMC Public Health*. 2013;13:1070. doi: 10.1186/1471-2458-13-1070
129. LoVerde B, Falck A, Donohue P, Hussey-Gardener B. Supports and barriers to the provision of human milk by mothers of African American preterm infants. *Adv Neonatal Care*. 2018;18:179–188. doi: 10.1097/ANC.0000000000000477
130. Burgess A, McDowell W, Ebersold S. Association between lactation and postpartum blood pressure in women with preeclampsia. *MCN Am J Matern Child Nurs*. 2019;44:86–93. doi: 10.1097/NMC.0000000000000502
131. Yu J, Pudwell J, Dayan N, Smith GN. Postpartum breastfeeding and cardiovascular risk assessment in women following pregnancy complications. *J Womens Health (Larchmt)*. 2020;29:627–635. doi: 10.1089/jwh.2019.7894
132. Countouris ME, Schwarz EB, Rossiter BC, Althouse AD, Berlacher KL, Jeyabalan A, Catov JM. Effects of lactation on postpartum blood pressure among women with gestational hypertension and preeclampsia. *Am J Obstet Gynecol*. 2016;215:241.e1–241.e8. doi: 10.1016/j.ajog.2016.02.046
133. Gunderson EP, Hurston SR, Ning X, Lo JC, Crites Y, Walton D, Dewey KG, Azevedo RA, Young S, Fox G, et al; Study of Women, Infant Feeding and Type 2 Diabetes After GDM Pregnancy Investigators. Lactation and progression to type 2 diabetes mellitus after gestational diabetes mellitus: a prospective cohort study. *Ann Intern Med*. 2015;163:889–898. doi: 10.7326/M15-0807
134. LeFevre ML; U.S. Preventive Services Task Force. Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med*. 2014;161:819–826. doi: 10.7326/M14-1884
135. Tolcher MC, Chu DM, Hollier LM, Mastrobattista JM, Racusin DA, Ramin SM, Sangi-Haghighi H, Aagaard KM. Impact of USPSTF recommendations for aspirin for prevention of recurrent preeclampsia. *Am J Obstet Gynecol*. 2017;217:365.e1–365.e8. doi: 10.1016/j.ajog.2017.04.035
136. Hoffman MK, Goudar SS, Kodkany BS, Metgud M, Somannavar M, Okitawutshu J, Lokangaka A, Tshetu A, Bose CL, Mwapule A, et al; ASPIRIN Study Group. Low-dose aspirin for the prevention of preterm delivery in nulliparous women with a singleton pregnancy (ASPIRIN): a randomised, double-blind, placebo-controlled trial. *Lancet*. 2020;395:285–293. doi: 10.1016/S0140-6736(19)32973-3
137. Katsi V, Georgantzios G, Kallistratos MS, Zerdas I, Makris T, Manolis AJ, Nihoyannopoulos P, Tousoulis D. The role of statins in prevention of preeclampsia: a promise for the future? *Front Pharmacol*. 2017;8:247. doi: 10.3389/fphar.2017.00247
138. Karalis DG, Hill AN, Clifton S, Wild RA. The risks of statin use in pregnancy: a systematic review. *J Clin Lipidol*. 2016;10:1081–1090. doi: 10.1016/j.jacl.2016.07.002
139. Aroda VR, Christophi CA, Edelstein SL, Zhang P, Herman WH, Barrett-Connor E, Delahanty LM, Montez MG, Ackermann RT, Zhuo X, et al; Diabetes Prevention Program Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10-year follow-up. *J Clin Endocrinol Metab*. 2015;100:1646–1653. doi: 10.1210/jc.2014-3761
140. Ratner RE, Christophi CA, Metzger BE, Dabelea D, Bennett PH, Pi-Sunyer X, Fowler S, Kahn SE; Diabetes Prevention Program Research Group. Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions. *J Clin Endocrinol Metab*. 2008;93:4774–4779. doi: 10.1210/jc.2008-0772
141. Syngelaki A, Nicolaides KH, Balani J, Hyer S, Akolekar R, Kotecha R, Pastides A, Shehata H. Metformin versus placebo in obese pregnant women without diabetes mellitus. *N Engl J Med*. 2016;374:434–443. doi: 10.1056/NEJMoa1509819
142. Romero R, Erez O, Hüttemann M, Maymon E, Panaitescu B, Conde-Agudelo A, Pacora P, Yoon BH, Grossman LI. Metformin, the aspirin of the 21st century: its role in gestational diabetes mellitus, prevention of preeclampsia and cancer, and the promotion of longevity. *Am J Obstet Gynecol*. 2017;217:282–302. doi: 10.1016/j.ajog.2017.06.003
143. Miller EC, Boehme AK, Chung NT, Wang SS, Lacey JV Jr, Lakshminarayan K, Zhong C, Woo D, Bello NA, Wapner R, et al. Aspirin reduces long-term stroke risk in women with prior hypertensive disorders of pregnancy. *Neurology*. 2019;92:e305–e316. doi: 10.1212/WNL.00000000000006815
144. McKinney J, Keyser L, Clinton S, Pagliano C. ACOG Committee Opinion No. 736: optimizing postpartum care. *Obstet Gynecol*. 2018;132:784–785. doi: 10.1097/AOG.00000000000002849
145. Brown HL, Warner JJ, Gianos E, Gulati M, Hill AJ, Hollier LM, Rosen SE, Rosser ML, Wenger NK; on behalf of the American Heart Association and the American College of Obstetricians and Gynecologists. Promoting risk identification and reduction of cardiovascular disease in women through collaboration with obstetricians and gynecologists: a presidential advisory from the American Heart Association and the American College of Obstetricians and Gynecologists. *Circulation*. 2018;137:e843–e852. doi: 10.1161/CIR.0000000000000582
146. NICE. *NICE Guideline [NG133]: Hypertension in Pregnancy: Diagnosis and Management*. 2019. Accessed February 10, 2021. <https://www.nice.org.uk/guidance/ng133>
147. Gamble DT, Brikinnis B, Myint PK, Bhattacharya S. Hypertensive disorders of pregnancy and subsequent cardiovascular disease: current national and international guidelines and the need for future research. *Front Cardiovasc Med*. 2019;6:55. doi: 10.3389/fcvm.2019.00055
148. Sprattling PM, Pryor ER, Moneyham LD, Hodges AL, White-Williams CL, Martin JN Jr. Effect of an educational intervention on cardiovascular disease risk perception among women with preeclampsia. *J Obstet Gynecol Neonatal Nurs*. 2014;43:179–189. doi: 10.1111/1552-6909.12296
149. Rich-Edwards JW, Stuart JJ, Skurnik G, Roche AT, Tsigas E, Fitzmaurice GM, Wilkins-Haug LE, Levkoff SE, Seely EW. Randomized trial to reduce cardiovascular risk in women with recent preeclampsia. *J Womens Health (Larchmt)*. 2019;28:1493–1504. doi: 10.1089/jwh.2018.7523
150. Rosendaal NTA, Pirkle CM. Age at first birth and risk of later-life cardiovascular disease: a systematic review of the literature, its limitation, and recommendations for future research. *BMC Public Health*. 2017;17:627. doi: 10.1186/s12889-017-4519-x
151. Celi AC, Seely EW, Wang P, Thomas AM, Wilkins-Haug LE. Caring for women after hypertensive pregnancies and beyond: implementation and integration of a postpartum transition clinic. *Matern Child Health J*. 2019;23:1459–1466. doi: 10.1007/s10995-019-02768-7
152. Hauspurg A, Lemon LS, Quinn BA, Binstock A, Larkin J, Beigi RH, Watson AR, Simhan HN. A postpartum remote hypertension monitoring protocol implemented at the hospital level. *Obstet Gynecol*. 2019;134:685–691. doi: 10.1097/AOG.0000000000003479
153. Mertens L, Braeken MAK, Bogaerts A. Effect of lifestyle coaching including telemonitoring and telecoaching on gestational weight gain and postnatal weight loss: a systematic review. *Telemed J E Health*. 2019;25:889–901. doi: 10.1089/tmj.2018.0139